双重TTK/PLK1抑制在TNBC中具有强大的抗癌活性,作为单一治疗和组合治疗

Elisa Zanini1, Nicole Forster-Gross1, Felix Bachmann1

  • 1Basilea Pharmaceutica International Ltd, Allschwil, Switzerland.

Frontiers in oncology
|August 26, 2024
PubMed
概括

一种新型的氨酸氨酸激酶 (TTK) 和波罗类激酶1 (PLK1) 的双重抑制剂,BAL0891,在临床前模型中显示出强大的抗癌活性,包括三阴性乳腺癌 (TNBC). 这种双重抑制策略为癌症治疗提供了一个有希望的新途径.

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K